71 related articles for article (PubMed ID: 20827166)
1. Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance.
; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Avit D; Kruy LS; McIntyre J; Say L; Gray G; Ekouévi DK; Dabis F
AIDS; 2010 Oct; 24(16):2481-8. PubMed ID: 20827166
[TBL] [Abstract][Full Text] [Related]
2. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
[TBL] [Abstract][Full Text] [Related]
3. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
Labarga P; Medrano J; Seclen E; Poveda E; Rodriguez-Novoa S; Morello J; de Mendoza C; Vispo E; Soriano V
AIDS; 2010 Mar; 24(5):777-9. PubMed ID: 20168201
[TBL] [Abstract][Full Text] [Related]
5. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Lapadula G; Costarelli S; Quiros-Roldan E; Calabresi A; Izzo I; Carosi G; Torti C
Clin Infect Dis; 2008 Apr; 46(7):1127-9. PubMed ID: 18444839
[No Abstract] [Full Text] [Related]
6. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
Muñoz de Benito RM; Arribas López JR
Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.
Si-Ahmed SN; Pradat P; Zoutendijk R; Buti M; Mallet V; Cruiziat C; Deterding K; Dumortier J; Bailly F; Esteban R; Wedemeyer H; Janssen HL; Zoulim F
Antiviral Res; 2011 Oct; 92(1):90-5. PubMed ID: 21767570
[TBL] [Abstract][Full Text] [Related]
8. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
[No Abstract] [Full Text] [Related]
9. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Podzamczer D; Andrade-Villanueva J; Clotet B; Taylor S; Rockstroh JK; Reiss P; Domingo P; Gellermann HJ; de Rossi L; Cairns V; Soriano V
HIV Med; 2011 Jul; 12(6):374-82. PubMed ID: 21518220
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.
Tosini W; Muller P; Prazuck T; Benabdelmoumen G; Peyrouse E; Christian B; Quertainmont Y; Bouvet E; Rabaud C
AIDS; 2010 Sep; 24(15):2375-80. PubMed ID: 20729709
[TBL] [Abstract][Full Text] [Related]
11. A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
De Clercq E
Expert Opin Pharmacother; 2009 Dec; 10(17):2935-7. PubMed ID: 19929712
[TBL] [Abstract][Full Text] [Related]
12. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
Chi BH; Sinkala M; Mbewe F; Cantrell RA; Kruse G; Chintu N; Aldrovandi GM; Stringer EM; Kankasa C; Safrit JT; Stringer JS
Lancet; 2007 Nov; 370(9600):1698-705. PubMed ID: 17997151
[TBL] [Abstract][Full Text] [Related]
13. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
14. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Redfield RR; Morrow JS
Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
[No Abstract] [Full Text] [Related]
15. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
Avihingsanon A; Lewin SR; Kerr S; Chang JJ; Piyawat K; Napissanant N; Matthews GV; Dore GJ; Bowden S; Lange J; Ruxrungtham K
Antivir Ther; 2010; 15(6):917-22. PubMed ID: 20834105
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
Blum MR; Chittick GE; Begley JA; Zong J
J Clin Pharmacol; 2007 Jun; 47(6):751-9. PubMed ID: 17519400
[TBL] [Abstract][Full Text] [Related]
17. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
Maserati R; De Silvestri A; Uglietti A; Colao G; Di Biagio A; Bruzzone B; Di Pietro M; Re MC; Tinelli C; Zazzi M;
AIDS; 2010 Apr; 24(7):1013-8. PubMed ID: 20124969
[TBL] [Abstract][Full Text] [Related]
18. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
[TBL] [Abstract][Full Text] [Related]
19. Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
N'Dri-Yoman T; Anglaret X; Messou E; Attia A; Polneau S; Toni T; Chenal H; Seyler C; Gabillard D; Wakasugi N; Eholié S; Danel C
Antivir Ther; 2010; 15(7):1029-34. PubMed ID: 21041918
[TBL] [Abstract][Full Text] [Related]
20. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
Nüesch R; Ananworanich J; Srasuebkul P; Chetchotisakd P; Prasithsirikul W; Klinbuayam W; Mahanontharit A; Jupimai T; Ruxrungtham K; Hirschel B
AIDS; 2008 Jan; 22(1):152-4. PubMed ID: 18090405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
